However, in our opinion, the lack of research verifying the potential benefits of the combination of SSRI and intranasal oxytocin therapy remains a missed opportunity, especially given the synaptic deficits in patients with PTSD and the potentially antidepressant role in promoting synaptic plasticity [95]. The gene discussed is OXT; the disease is post-traumatic stress disorder.